RaySearch Laboratories AB (publ) (RAY-B.ST)
| Previous close | 116.60 |
| Open | 116.60 |
| Bid | 115.60 x 0 |
| Ask | 116.00 x 0 |
| Day's range | 110.80 - 116.60 |
| 52-week range | 55.60 - 123.80 |
| Volume | |
| Avg. volume | 79,019 |
| Market cap | 3.997B |
| Beta (5Y monthly) | 1.23 |
| PE ratio (TTM) | 62.37 |
| EPS (TTM) | 1.86 |
| Earnings date | 17 May 2024 |
| Forward dividend & yield | 0.70 (0.60%) |
| Ex-dividend date | 23 May 2024 |
| 1y target est | 135.00 |
PR NewswireRaySearch and Mevion - A synergy of innovation transforming proton therapy
RaySearch Laboratories AB (publ) is proud to announce the continued commitment with Mevion Medical Systems, the leading global provider of compact proton therapy solutions, to develop new proton therapy solutions in support of current and emerging technologies. Together RaySearch and Mevion re-imagine novel solutions to advance the use of new proton therapy technologies and empower medical providers to rapidly and efficiently bring next-generation proton therapy services to their patients.
PR NewswireSouthwest Florida Proton selects RayStation
Southwest Florida Proton is establishing a proton center between Naples and Fort Myers, Florida, that will be the first cancer treatment center on Florida's west coast to offer proton therapy, an effective treatment option for cancers of the brain and spine, breast, esophagus, head and neck, liver, lung, eye, pancreas and prostate, lymphoma, and soft tissue sarcomas. It is also considered standard of care when compared with conventional radiation for most pediatric indications. The center will b
PR NewswireThe Australian Bragg Centre for Proton Therapy and Research selects RayCare
RaySearch Laboratories AB (publ) announces that the Australian Bragg Centre for Proton Therapy and Research (ABCPTR) in Adelaide, Australia has placed an order for the oncology information system RayCare®*.
